Cargando…
Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resistance. Typically, cisplatin resistance is not restricted to a single mechanism demanding for a systems pharmacology approach to understand a whole cell’s reaction to the drug. In this study, the cell...
Autores principales: | Sarin, Navin, Engel, Florian, Rothweiler, Florian, Cinatl, Jindrich, Michaelis, Martin, Frötschl, Roland, Fröhlich, Holger, Kalayda, Ganna V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877628/ https://www.ncbi.nlm.nih.gov/pubmed/29518977 http://dx.doi.org/10.3390/ijms19030767 |
Ejemplares similares
-
Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G(2)/M cell cycle arrest
por: Sarin, Navin, et al.
Publicado: (2017) -
ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015) -
Increased HRD score in cisplatin resistant penile cancer cells
por: Winkelmann, Ria, et al.
Publicado: (2022) -
Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin
por: Dilruba, Shahana, et al.
Publicado: (2020) -
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status
por: Michaelis, Martin, et al.
Publicado: (2015)